Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal potency and high specificity
Y. Ou, M. Liu, K. Zhan, W. Wu, J. Huang, H. Sun, H. Zheng, X. Yu, H. Gong, Z. Han, A. Chen, Y. Liao, Y. Lin, G. Liu, Q. Liu, , S. Zhong
This study develops a high-affinity, specific TCR targeting NY-ESO-1 through engineering and screening, showing efficacy in tumor models and approval for clinical trials.
bioRxiv · Oct 12, 2022 · PreprintImmunology